Psychotic Disorder Clinical Trial
— DROPOfficial title:
The Effect of D-serine as add-on Therapy in Recent-onset Psychosis
Verified date | September 2022 |
Source | Psychiatric Hospital of the University of Basel |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In psychotic disorders, negative symptoms and cognitive impairment are difficult to treat with antipsychotics, which are mostly effective for positive symptoms. However, it is important that negative symptoms and cognitive impairment are treated as well, as they both play a large part in the acute episode and long-term course of schizophrenia outcome. Previous studies have used D-serine as add-on treatment in patients with psy-chotic disorders and high-risk patients, with positive results. So far, no study has investigated the effects in a sample of recent-onset psychosis patients. Therefore, this study will include 30 patients (18-50 years old) with recent-onset psychosis. In addition to their regular treatment, patients will receive either D-serine (2 g/d) or placebo for 6 weeks. D-serine is an amino-acid naturally occurring in the brain which is prescription-free available as nutritional supplement. The primary outcome measure is total score on the Positive and Negative Syndrome Scale (PANSS). Secondary measure-ments include PANSS subscales, neurocognitive tests, (f)MRI, and EEG
Status | Terminated |
Enrollment | 3 |
Est. completion date | August 31, 2022 |
Est. primary completion date | August 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: - Age 18-50 - Recent onset psychosis (< 5 years of overt psychotic symptoms) - Able to read and understand study procedures and participant's information Exclusion Criteria: - Clozapine use - Suicidal ideation - Psychotic disorders and symptoms associated with general medical conditions or substance abuse - BMI > 30 - Renal impairment (history and creatin levels (< 80 ug/L for woman and < 97 ug/L for men)) - Hearing impairment - Current or past (< 6 months) enrolment in another clinical trial with the primary outcome to improve symptoms - Pregnant or lactating women (pregnancy test) |
Country | Name | City | State |
---|---|---|---|
Switzerland | UPK Basel | Basel | Basel-Stadt |
Lead Sponsor | Collaborator |
---|---|
Dragos Inta |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Total symptom severity | total score on the Positive and Negative Syndrome Scale (PANSS). Lower scores indicate better outcome (min. 30 - max. 120). | change from baseline to 6 weeks | |
Secondary | Subscales symptom severity | Subscores (5-factor model) on the Positive and Negative Syndrome Scale (PANSS). Lower scores indicate better outcome. | change from baseline to 6 weeks | |
Secondary | Symptom severity and treatment response | measured with the Clinical Global Impression Scale (CGI), lower scores indicate a better outcome | change from baseline to 6 weeks | |
Secondary | Resting-state microstates | measured with resting-state electroencephalography (EEG). large-scale neural networks are investigated with EEG microstates Ocillations in the theta-band (4-7 Hz) and gamma-band (>30 Hz) will be assessed.
measured with resting-state electroencephalography (EEG). Ocillations in the theta-band (4-7 Hz) and gamma-band (>30 Hz) will be assessed. |
change from baseline to 6 weeks | |
Secondary | Mismatch Negativity (MMN) | measured with EEG | change from baseline to 6 weeks | |
Secondary | Intelligence | Part of neurocognitive testing. Higher scores indicate better outcome. | change from baseline to 6 weeks | |
Secondary | Attention and processing speed | Part of neurocognitive testing. Higher scores indicate better outcome. | change from baseline to 6 weeks | |
Secondary | Executive functioning | Part of neurocognitive testing. Higher scores indicate better outcome. | change from baseline to 6 weeks | |
Secondary | Memory | Part of neurocognitive testing. Higher scores indicate better outcome. | change from baseline to 6 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02306551 -
Well Being And Resilience: Mechanisms of Transmission of Health and Risk
|
||
Active, not recruiting |
NCT00627029 -
Evaluation of Programs of Coordinated Care and Disease Management
|
N/A | |
Terminated |
NCT00049738 -
Screening for Childhood-Onset Psychotic Disorders
|
N/A | |
Withdrawn |
NCT01724372 -
The Role of Antidepressants or Antipsychotics in Preventing Psychosis
|
N/A | |
Completed |
NCT00716755 -
Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia.
|
N/A | |
Completed |
NCT00498550 -
Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual
|
Phase 4 | |
Completed |
NCT01473550 -
Mental Health Engagement Network (MHEN)
|
N/A | |
Completed |
NCT01207219 -
Yoga and Aerobic Exercise in Psychosis
|
N/A | |
Completed |
NCT00397033 -
Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.
|
Phase 3 | |
Recruiting |
NCT04945278 -
Study of Self-Recognition and Self/Other Distinction Disorders in Patients With Psychological Vulnerability
|
N/A | |
Completed |
NCT03955250 -
Mobile After-Care Support App: Pilot RCT
|
N/A | |
Completed |
NCT00287352 -
Study of Amantadine for Weight Stabilization During Olanzapine Treatment
|
Phase 1 | |
Completed |
NCT00005658 -
Glycine to Treat Psychotic Disorders in Children
|
Phase 2 | |
Terminated |
NCT00169026 -
Alcoholism and Schizophrenia: Effects of Clozapine
|
Phase 4 | |
Completed |
NCT00001482 -
New Drugs in the Treatment of Mood Disorders
|
Phase 2 | |
Terminated |
NCT03671005 -
Mindfulness-based Group Therapy for Inpatients With Schizophrenia Spectrum Disorders
|
N/A | |
Completed |
NCT00156715 -
Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
|
Phase 4 | |
Completed |
NCT00095524 -
Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder
|
Phase 3 | |
Completed |
NCT03667729 -
The Effects of Progressive Muscle Relaxation Therapy in Patients With Schizophrenia
|
N/A | |
Completed |
NCT00001656 -
Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
|
Phase 4 |